EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaFebruary 23, 2024
US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myelomaAccess, MPE, MyelomaFebruary 22, 2024
EMA CHMP gives positive opinion on CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaJanuary 30, 2024
MPE announces partnership in EU consortium project CERTAINTY: advancing cancer care through virtual twins in personalised immunotherapyMyelomaDecember 19, 2023
ASH 2023 | Myeloma and AL amyloidosis updatesAL amyloidosis, Conferences, MPE, MyelomaDecember 15, 2023
Sign up for the MPE webinar on ASH 2023 myeloma and AL amyloidosis highlightsAL amyloidosis, Conferences, MPE, MyelomaDecember 9, 2023
The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myelomaAccess, MyelomaDecember 8, 2023
EMA CHMP gives positive recommendation to elranatamab for the treatment of relapsed or refractory myelomaAccess, MPE, MyelomaOctober 13, 2023
